



an Open Access Journal by MDPI

## Kidney Disease: From Pathophysiology to Novel Therapeutic Approaches

Guest Editor:

### Prof. Dr. Gener Ismail

1. Department of Nephrology,  
"Carol Davila" University of  
Medicine and Pharmacy, 020021  
Bucharest, Romania  
2. Department of Nephrology,  
Fundeni Clinical Institute, 022328  
Bucharest, Romania

Deadline for manuscript  
submissions:  
**closed (31 May 2022)**

### Message from the Guest Editor

Dear Colleagues,

This Special Issue "Kidney Disease: From Pathophysiology to Novel Therapeutic Approaches" invites contributions both of original articles and reviews dedicated to improving the knowledge on kidney disorders, focusing on topics such as pathophysiology, renal pathology, biomarkers of renal disorders and novel therapeutic approaches and can include not only the spectrum of glomerular disorders, but also genetic disorders, tubulopathies, diabetic nephropathy and renal transplantation.

Renal disorders have an increasing contribution to the global health burden, while end-stage kidney disease is among the leading causes of death worldwide. Tremendous advances have been achieved in recent decades regarding the understanding of the pathophysiology of kidney disorders, having been translated into improved outcomes of patients with chronic kidney disease and the development of novel therapies. Nevertheless, there are still many areas of uncertainty requiring addressing, with this Special Issue's objective being to approach several of these issues.

Prof. Dr. Gener Ismail  
*Guest Editor*



[mdpi.com/si/105569](https://mdpi.com/si/105569)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)